業績集

英語論文

2023年

1. Ishihara M, Nishida Y, Kitano S, Kawai A, Muraoka D, Momose F, Harada N, Miyahara Y, Seo N, Hattori H, Takada K, Emori M, Kakunaga S, Endo M, Matsumoto Y, Sasada T, Sato E, Yamada T, Matsumine A, Nagata Y, Watanabe T, Kageyama S, Shiku H. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma Int J Cancer. 2023 Jun 15;152(12):2554-2566. doi: 10.1002/ijc.34453. Epub 2023 Feb 17.PMID: 36727538 Clinical Trial.

 

2022年

1. Ishihara M, Kitano S, Kageyama S, Miyahara Y, Yamamoto N, Kato H, Mishima H, Hattori H, Funakoshi T, Kojima T, Sasada T, Sato E, Okamoto S, Tomura D, Nukaya I, Chono H, Mineno J, Kairi MF, Diem Hoang Nguyen P, Simoni Y, Nardin A, Newell E, Fehlings M, Ikeda H, Watanabe T, Shiku H. NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome J Immunother Cancer. 2022 Jun;10(6):e003811. doi: 36/jitc-2021-003811.PMID: 35768164 Free PMC Clinical Trial

2.Muraoka D, Harada N, Shiku H, Akiyoshi K. Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance J Control Release. 2022 Jul;347:175-182. doi: 10.1016/j.jconrel.2022.05.004. Epub 2022 May 11.PMID: 35526613 Review.

3.Bulygin AS, Khantakova JN, Shkaruba NS, Shiku H, Sennikov SS The role of metabolism on regulatory T cell development and its impact in tumor and transplantation immunity Front Immunol. 2022 Dec 7;13:1016670. doi: 10.3389/fimmu.2022.1016670. eCollection 2022.PMID: 36569866 Free PMC article. Review.

4.Gong W, Wang L, Schubert ML, Kleist C, Neuber B, Wang S, Yang M, Hückelhoven-Krauss A, Wu D, Schmitt A, Müller-Tidow C, Shiku H, Schmitt M, Sellner L. HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma. Biomedicines. 2022 Feb 3;10(2):373. doi: 10.3390/biomedicines10020373.PMID: 35203582 Free PMC article.

5. Kurilin V, Kulikova E, Shevchenko J, Lopatnikova J, Obleukhova I, Khantakova J, Maksyutov A, Kuznetsova M, Khristin A, Kiryshina N, Kozlov V, Sidorov S, Sokolov A, Vitsin A, Shiku H, Sennikov S. Dendritic cells transfected with a polyepitope DNA construct stimulate an antitumor cytotoxic response in various tumors Mol Clin Oncol. 2022 Oct 3;17(5):155. doi: 10.3892/mco.2022.2588. eCollection 2022 Nov.PMID: 36325297 Free PMC article.

6.Seo N, Nakamura J, Kaneda T, Tateno H, Shimoda A, Ichiki T, Furukawa K, Hirabayashi J, Akiyoshi K, Shiku H. Distinguishing functional exosomes and other extracellular vesicles as a nucleic acid cargo by the anion-exchange method. J Extracell Vesicles. 2022 Mar;11(3):e12205. doi: 10.1002/jev2.12205.PMID: 35289089 Free PMC article.

7.Nakase K, Miwa H, Shiku H. Is CD22 positive acute myeloid leukemia, a distinct myeloid disease entity? J Oncology 2022; 2(1): 1029, 2022.

8.Nakase K, Tanaka I, Tawara I, Shiku H. CD22 expression in acute myeloid leukemia: close correlation with interleukin-2 receptor α-chain (CD25) expression and poor prognosis Leuk Lymphoma. 2022 Sep;63(9):2251-2253. doi: 10.1080/10428194.2022.2062346. Epub 2022 Apr 20.PMID: 35442136 No abstract available.

9.Shimoda A, Miura R, Tateno H, Seo N, Shiku H, Sawada SI, Sasaki Y, Akiyoshi K.Assessment of Surface Glycan Diversity on Extracellular Vesicles by Lectin Microarray and Glycoengineering Strategies for Drug Delivery ApplicationsSmall Methods. 2022 Feb;6(2):e2100785. doi: 10.1002/smtd.202100785. Epub 2021 Dec 1.PMID: 35174988

10.Nagata Y, Kageyama S, Ishikawa T, Kokura S, Okayama T, Abe T, Murakami M, Otsuka K, Ariyoshi T, Kojima T, Taniguchi K, Kobayashi S, Shimada H, Yajima S, Suzuki T, Hirano S, Tsuchikawa T, Shichinohe T, Ueda S, Kanetaka K, Yoneda A, Wada H, Doki Y, Yamaue H, Katsuda M, Ohi M, Yasuda H, Kondo K, Kataoka M, Kodera Y, Koike M, Shiraishi T, Miyahara Y, Goshima N, Fukuda E, Yamaguchi K, Sato E, Ikeda H, Yamada T, Osako M, Hirai K, Miyamoto H, Watanabe T, Shiku H. Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy BMJ Open. 2022 Nov 14;12(11):e065109. doi: 36/bmjopen-2022-065109.PMID: 36375974 Free PMC article.

11.Okumura S, Ishihara M, Kiyota N, Yakushijin K, Takada K, Kobayashi S, Ikeda H, Endo M, Kato K, Kitano S, Matsumine A, Nagata Y, Kageyama S, Shiraishi T, Yamada T, Horibe K, Takesako K, Miwa H, Watanabe T, Miyahara Y, Shiku H. Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial BMJ Open. 2022 Nov 14;12(11):e065109. doi: mjopen-2022-065109.PMID: 36375974 Free PMC article

2021年

  1. Watanabe T. The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential. Int J Mol Sci. 22: 5352, 2021. doi:10.3390/ijms22105352.
  2. Watanabe T. Realization of Osteolysis, Angiogenesis, Immunosuppression, and Drug Resistance by Extracellular Vesicles: Roles of RNAs and Proteins in Their Cargoes and of Ectonucleotidases of the Immunosuppressive Adenosinergic Noncanonical Pathway in the Bone Marrow Niche of Multiple Myeloma. Cancers (Basel). 13: 2969, 2021. doi: 10.3390/cancers13122969.
  3. Ishikawa T, Kageyama S, Miyahara Y, Okayama T, Kokura S, Wang L, Sato E, Yagita H, Itoh Y, Shiku H.Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. Cancer Immunol Immunother. 2021 Mar 22. doi: 10.1007/s00262-021-02892-w.Online ahead of print.PMID: 33751208
  4. Shimoda A, Miura R, Tateno H, Seo N, Shiku H, Sawada SI, Sasaki Y, Akiyoshi K. Assessment of Surface Glycan Diversity on Extracellular Vesicles by Lectin Microarray and Glycoengineering Strategies for Drug Delivery Applications Small Methods. 2022 Feb;6(2):e2100785. doi: 10.1002/smtd.202100785. Epub 2021 Dec 1.PMID: 35174988
  5. Gong W, Wang L, Stock S, Ni M, Schubert ML, Neuber B, Kleist C, Hückelhoven-Krauss A, Wu D, üller-Tidow C, Schmitt A, Shiku H, Schmitt M, Sellner L. Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells Cells. 2021 Jan 14;10(1):152. doi: 010152.PMID: 33466646 Free PMC article.

 

2020年

 

1.Fukuda E, Mori M, Shiku H, Miyahara Y, Kawamura Y, Ogawa K, Ogura T, Goshima N. Development of INSOL-tag for proteome-wide protein handling and its application in protein array analysis. Genes Cells. 2020 Jan;25(1):41-53. doi: 10.1111/gtc.12735. Epub 2019 Dec 3.PMID:317331612.

2.Sukegawa K, Shitaoka K, Hamana H, Kobayashi E, Miyahara Y, Fujii K, Tsuda K, Saeki S, Nagata T, Ozawa T, Saito S, Fujii T, Muraguchi A, Shiku H, Kishi H. Relationship between T cell receptor clonotype and PD-1 expression of tumor-infiltrating lymphocytes in colorectal cancer Eur J Immunol. 2020 Oct;50(10):1580-1590. doi: 10.1002/eji.201948399. Epub 2020 Jun 3.PMID: 32441316Free article.

3.Ishihara M, Kageyama S, Miyahara Y, Ishikawa T, Ueda S, Soga N, Naota H, Mukai K, Harada N, Ikeda H, Shiku H. MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours BMC Cancer. 2020 Jun 29;20(1):606. doi: 10.1186/s12885-020-07098-4.PMID: 32600281 Free PMC article.

4.Kawamura K, Tanaka Y, Nakasone H, Ishihara Y, Kako S, Kobayashi S, Tanaka Y, Ohmori T, Uchimaru K, Okamoto S, Mineno J, Shiku H, Nishimura S, Kanda Y. Development of a Unique T Cell Receptor Gene-Transferred Tax-Redirected T Cell Immunotherapy for Adult T Cell Leukemia Biol Blood Marrow Transplant. 2020 Aug;26(8):1377-1385. doi: 10.1016/j.bbmt.2020.04.006. Epub 2020 Apr 18.PMID: 32311478Free article

5.Imai N, Tawara I, Yamane M, Muraoka D, Shiku H, Ikeda H. CD4+ T cells support polyfunctionality of cytotoxic CD8+ T cells with memory potential in immunological control of tumor Cancer Sci. 2020 Jun;111(6):1958-1968. doi: 10.1111/cas.14420. Epub 2020 May 12.PMID: 32304127 Free PMC article.

6.Ishihara M, Tono Y, Miyahara Y, Muraoka D, Harada N, Kageyama S, Sasaki T, Hori Y, Soga N, Uchida K, Shiraishi T, Sato E, Kanda H, Mizuno T, Webster GA, Ikeda H, Katayama N, Sugimura Y, Shiku H. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. Cancer Immunol Immunother. 2020 Jan 24. doi: 10.1007/s00262-020-02483-1. [Epub ahead of print PMID:31980914

2019年

  1. Kakimoto T, Matsumine A, Kageyama S, Asanuma K, Matsubara T, Nakamura T, Iino T, Ikeda H, Shiku H, Sudo A. Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma. Oncol Lett 17(4):3937-3943,2019.
  2. Muraoka D, Seo N, Hayashi T, Tahara Y, Fujii K, Tawara I, Miyahara Y, Okamori K, Yagita H, Imoto S, Yamaguchi R, Komura M, Miyano S, Goto M, Sawada SI, Asai A,Ikeda H, Akiyoshi K, Harada N, Shiku H. Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. J Clin Invest 129(3):1278-1294,2019.
  3.  Oda H, Ishihara M, Miyahara Y, Nakamura J, Kozuka Y, Iwasa M, Tsunoda A,Yamashita Y, Saito K, Mizuno T, Shiku H, Katayama N. First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer. Case Rep Oncol 8;12(1):147-156,2019.
  4. Park EJ, Prajuabjinda O, Soe ZY, Darkwah S, Appiah MG, Kawamoto E, Momose F,Shiku H, Shimaoka M. Exosomal regulation of lymphocyte homing to the gut. Blood 8;3(1):1-11,2019.
  5.  Gong W, Hoffmann JM, Stock S, Wang L, Liu Y, Schubert ML, Neuber B, Hückelhoven-Krauss A, Gern U, Schmitt A, Müller-Tidow C, Shiku H, Schmitt M, Sellner L.Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cellsCancer Immunol Immunother. 2019 Jul;68(7):1195-1209. doi: 10.1007/s00262-019-02354-4. Epub 2019 Jun 8.PMID: 31177329
  6.  Fukuda E, Mori M, Shiku H, Miyahara Y, Kawamura Y, Ogawa K, Ogura T, Goshima N. Development of INSOL-tag for proteome-wide protein handling and its application in protein array analysis Genes Cells. 2020 Jan;25(1):41-53. doi: 10.1111/gtc.12735. Epub 2019 Dec 3.PMID: 31733161 Free article.

2018年

  1. Ueda S, Miyahara Y, Nagata Y, Sato E, Shiraishi T, Harada N, Ikeda H, Shiku H,Kageyama S. NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma. Oncotarget13;9(89):35997-36011,2018.
  2. Seo N, Akiyoshi K, Shiku H. Exosome-mediated regulation of tumor immunology. Cancer Sci 109(10):2998-3004,2018.
  3. Akahori Y, Wang L, Yoneyama M, Seo N, Okumura S, Miyahara Y, Amaishi Y, Okamoto S, Mineno J, Ikeda H, Maki T, Fujiwara H, Akatsuka Y, Kato T, Shiku H. Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination. Blood 132(11):1134-1145,2018.
  4. Fujiwara-Kuroda A, Kato T, Abiko T, Tsuchikawa T, Kyogoku N, Ichinokawa M,Tanaka K, Noji T, Hida Y, Kaga K, Matsui Y, Ikeda H, Kageyama S, Shiku H, Hirano S. Prognostic value of MAGEA4 in primary lung cancer depends on subcellular localization and p53 status. Int J Oncol 53(2):713-724,2018.
  5. Wada M, Tsuchikawa T, Kyogoku N, Abiko T, Miyauchi K, Takeuchi S, Kuwatani T, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Hirano S. Clinical Implications of CD4(+)CD25(+)Foxp3(+)Regulatory T Cell Frequencies After CHP-MAGE-A4 Cancer Vaccination. Anticancer Res 38(3):1435-1444,2018.
  6. Abiko T, Tsuchikawa T, Miyauchi K, Wada M, Kyogoku N, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Hirano S. Serum immunoglobulin Eresponse as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination. Oncol Lett 15(3):3703-3711,2018.
  7. Tono Y, Ishihara M, Miyahara Y, Tamaru S, Oda H, Yamashita Y, Tawara I, Ikeda H, Shiku H, Mizuno T, Katayama N. Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers. Oncotarget 16;9(19):14909-14921,2018.
  8. Seo N, Shirakura Y, Tahara Y, Momose F, Harada N, Ikeda H, Akiyoshi K, Shiku H. Activated CD8(+) T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells. Nat Commun 30;9(1):435,2018.

2017年

  1. Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y, Ikeda H,Tanimoto K, Terakura S, Murata M, Inaguma Y, Masuya M, Inoue N, Kidokoro T, Okamoto S, Tomura D, Chono H, Nukaya I, Mineno J, Naoe T, Emi N, Yasukawa M, Katayama N, Shiku H. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood 2;130(18):1985-1994,2017.
  2. Tanaka Y, Ohishi K, Sawai T, Iwasaki H, Kageyama S, Masuya M, Matsumoto T, Tanigawa T, Wada H, Shiku H, Ito M, Katayama N. Attempt to Harvest a Sufficient Number of Mononuclear Cells in an Appropriate Blood Product Volume By Modification of the Default Apheresis Setting. Ther Apher Dial 21(5):507-511,2017.
  3. Muraoka D, Seo N, Hayashi T, Hyuga-Amaike C, Okamori K, Tawara I, Harada N,Shiku H. Signal-transducing adaptor protein-2 promotes generation of functional long-term memory CD8+ T cells by preventing terminal effector differentiation. Oncotarget 9;8(19):30766-30780,2017.
  4. Fujii K, Miyahara Y, Harada N, Muraoka D, Komura M, Yamaguchi R, Yagita H, Nakamura J, Sugino S, Okumura S, Imoto S, Miyano S, Shiku H. Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors. Oncoimmunology 20;6(5):e1306617,2017.

2016年

  1. Kyogoku N, Ikeda H, Tsuchikawa T, Abiko T, Fujiwara A, Maki T, Yamamura Y,Ichinokawa M, Tanaka K, Imai N, Miyahara Y, Kageyama S, Shiku H, Hirano S. Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel. Oncol Lett 12(6):4493-4504,2016.
  2. Tanaka H, Fujiwara H, Ochi F, Tanimoto K, Casey N, Okamoto S, Mineno J, Kuzushima K, Shiku H, Sugiyama T, Barrett AJ, Yasukawa M. Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.
    Clin Cancer Res 22(17):4405-16,2016.
  3. Wang L, Ma N, Okamoto S, Amaishi Y, Sato E, Seo N, Mineno J, Takesako K, KatoT, Shiku H. Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunology 5(9):e1211218,2016.
  4. Kashima H, Momose F, Umehara H, Miyoshi N, Ogo N, Muraoka D, Shiku H, Harada N, Asai A. Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity. PLoS One 10;11(6):e0156643,2016.
  5. Casey NP, Fujiwara H, Tanimoto K, Okamoto S, Mineno J, Kuzushima K, Shiku H, Yasukawa M. A Functionally Superior Second-Generation Vector Expressing an Aurora Kinase-A-Specific T-Cell Receptor for Anti-Leukaemia Adoptive Immunotherapy. PLoS One 7;11(6):e0156896,2016.
  6. Miyauchi K, Tsuchikawa T, Wada M, Abiko T, Kyogoku N, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Hirano S. Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination. Immunotherapy 8(5):527-40,2016.
  7. Momose F, Seo N, Akahori Y, Sawada S, Harada N, Ogura T, Akiyoshi K, Shiku H. Guanine-Rich Sequences Are a Dominant Feature of Exosomal microRNAs across the Mammalian Species and Cell Types. PLoS One 11(4):e0154134,2016.
  8. Akane K, Kojima S, Mak TW, Shiku H, Suzuki H. CD8+CD122+CD49dlow regulatory T cells maintain T-cell homeostasis by killing activated T cells via Fas/FasL-mediated cytotoxicity. Proc Natl Acad Sci U S A 113(9):2460-5,2016.
  9. Sato YT, Umezaki K, Sawada S, Mukai SA, Sasaki Y, Harada N, Shiku H, Akiyoshi K. Engineering hybrid exosomes by membrane fusion with liposomes. Sci Rep 6:21933,2016.

2015年

  1. Matsuzaki J, Tsuji T, Luescher IF, Shiku H, Mineno J, Okamoto S, Old LJ,Shrikant P, Gnjatic S, Odunsi K. Direct tumor recognition by a human CD4(+)T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Sci Rep 5:14896,2015.
  2. Miyazaki K, Yamaguchi M, Imai H, Kobayashi K, Tamaru S, Kobayashi T, Shiku H, Katayama N. Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression. Int J Hematol 102(2):188-94,2015.
  3. Ikeda H, Shiku H. Adoptive immunotherapy of cancer utilizing genetically engineered lymphocytes. Cancer Immunol Immunother 64(7):903-9,2015.
  4. Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S, Naota H, Ohishi K, Shiraishi T, Inoue N, Tanabe M, Kidokoro T, Yoshioka H, Tomura D, Nukaya I, Mineno J, Takesako K, Katayama N, Shiku H. Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer.　Clin Cancer Res 15;21(10):2268-77,2015.

2014年

  1. Saito T, Wada H, Yamasaki M, Miyata H, Nishikawa H, Sato E, Kageyama S, Shiku H, Mori M, Doki Y. High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine 32(45):5901-7,2014.
  2. Nishikawa K, Seo N, Torii M, Ma N, Muraoka D, Tawara I, Masuya M, Tanaka K,Takei Y, Shiku H, Katayama N, Kato T. Interleukin-17 induces an atypical M2-like macrophage subpopulation that regulates intestinal inflammation. PLoS One 9(9):e108494,2014.
  3. Muraoka D, Harada N, Hayashi T, Tahara Y, Momose F, Sawada S, Mukai SA,Akiyoshi K, Shiku H. Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity. ACS Nano 8(9):9209-18,2014.
  4. Ishihara M, Seo N, Mitsui J, Muraoka D, Tanaka M, Mineno J, Ikeda H, Shiku H. Systemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor. PLoS One 9(8):e104669,2014.
  5. Hosoi H, Ikeda H, Imai N, Amaike C, Wang L, Orito Y, Yamane M, Ueno H, Ideno M, Nukaya I, Enoki T, Mineno J, Takesako K, Hirano S, Shiku H.Stimulation through very late antigen-4 and -5 improves the multifunctionality and memory formation of CD8⁺ T cells. Eur J Immunol 44(6):1747-58,2014.